💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Fesoterodine Fumarate

CHEMBL1201765 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
527.6 g/mol
LogP
—
Phase
4

This fumarate salt form of fesoterodine is used to treat overactive bladder by blocking the nerve signals that cause sudden, uncontrollable urges to urinate. It is the active form delivered in extended-release tablets to provide consistent symptom control throughout the day.

Molekularmasse

527,6000 g/mol

TPSA

124,00 Ų

Wirkmechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C30H41NO7

                    

                    
                    

                        
HBD / HBA

                        
3 / 8

                    

                    
                    

                        
Rotierbare Bindungen

                        
13

                    

                    
                    
                    

                        
Schwere Atome

                        
38

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
This fumarate salt form of fesoterodine is used to treat overactive bladder by blocking the nerve signals that cause sudden, uncontrollable urges to urinate. It is the active form delivered in extended-release tablets to provide consistent symptom control throughout the day.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Fesoterodine Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201765.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9849808.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.